Next 10 |
home / stock / pfe / pfe articles
Scores of patients are reportedly taking legal action against pharmaceutical giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S...
An investigational gene therapy, dubbed scAAV9/JeT-GAN, for a rare neurodegenerative disease, giant axonal neuropathy (GAN), that begins in early c...
Money manager Cathie Wood’s Ark Invest has a favorite biotech holding now, going by the firm’s recent buying activity. What Happened: A...
Pfizer Inc’s (NYSE:PFE) German partner, BioNTech SE (NASDAQ:BNTX), reported fourth-quarter 2023 EPS of fiscal year Q4 GAAP EPS of €1.90 ...
Pfizer Inc (NYSE:PFE) plans to slash its stake to approximately 24% in Consumer healthcare giant Haleon Plc (NYSE:HLN)&nbs...
Thursday, Immuneering Corporation (NASDAQ:IMRX) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-...
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
Pfizer Inc. (NYSE: PFE) shares closed slightly higher on Wednesday. The New York-based pharmaceutical giant recently said that the European Commis...
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. (NYSE: PFE) as his final ...
News, Short Squeeze, Breakout and More Instantly...
2024-03-26 04:17:00 ET Few things are more satisfying than watching a steadily growing stream of passive income flow into your brokerage account. If you've been holding back from investing because you think you can't afford to, I've got good news. Now that brokerages have done away with tra...
2024-03-25 04:50:00 ET Cathie Wood and high dividend yields go together like... well, it's hard to finish that sentence because they don't go together at all. Wood and her Ark Invest funds are known for investing in innovative growth stocks, not stocks with exceptionally attractive dividend...
2024-03-23 06:45:00 ET Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks. Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (NASDAQ: AXSM) , CRISPR Therapeutics (NASDAQ: CRSP)...